ATE481109T1 - Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden - Google Patents

Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden

Info

Publication number
ATE481109T1
ATE481109T1 AT02773789T AT02773789T ATE481109T1 AT E481109 T1 ATE481109 T1 AT E481109T1 AT 02773789 T AT02773789 T AT 02773789T AT 02773789 T AT02773789 T AT 02773789T AT E481109 T1 ATE481109 T1 AT E481109T1
Authority
AT
Austria
Prior art keywords
antibodies
hiv
antibody fragments
nucleic acids
env
Prior art date
Application number
AT02773789T
Other languages
English (en)
Inventor
Dimiter Dimitrov
Maxime Moulard
Xiadong Xiao
Yuuei Shu
Sanjay Phogat
Mei-Yun Zhang
Dennis Burton
Original Assignee
Us Gov Health & Human Serv
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Scripps Research Inst filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE481109T1 publication Critical patent/ATE481109T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02773789T 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden ATE481109T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32970901P 2001-10-16 2001-10-16
PCT/US2002/033165 WO2003033666A2 (en) 2001-10-16 2002-10-16 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes

Publications (1)

Publication Number Publication Date
ATE481109T1 true ATE481109T1 (de) 2010-10-15

Family

ID=23286644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02773789T ATE481109T1 (de) 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden

Country Status (7)

Country Link
US (2) US7223844B2 (de)
EP (1) EP1450857B1 (de)
AT (1) ATE481109T1 (de)
AU (1) AU2002337885B1 (de)
CA (1) CA2463931A1 (de)
DE (1) DE60237704D1 (de)
WO (1) WO2003033666A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951947B2 (en) 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
JP2006506948A (ja) * 2002-04-09 2006-03-02 チルドレンズ ホスピタル， インコーポレイテッド 抗体遺伝子送達およびそのための組換えａａｖ
CA2484930A1 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2003095492A1 (en) 2002-05-06 2003-11-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
GB0218817D0 (en) * 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
EP1627046A4 (de) * 2003-05-06 2008-02-13 Scripps Research Inst Bindungsmoleküle mit domänenaustausch, verwendungsverfahren und herstellungsverfahren
WO2006071206A2 (en) * 2003-09-29 2006-07-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulins whith potent and broad antiviral activity
JP2007529718A (ja) * 2004-03-12 2007-10-25 ザ スクリップス リサーチ インスティチュート 蛋白質活性の検出および定量のための蛍光シグナル発光型生細胞バイオセンサー分子ならびに色素
US8637234B2 (en) 2004-04-16 2014-01-28 Uab Research Foundation Molecular scaffolds for HIV-1 epitopes
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
US8647818B2 (en) 2005-02-18 2014-02-11 UAB Research Foundation, University of Alabama—Birmingham Molecular scaffolds for HIV-1 immunogens
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
CA2616189C (en) * 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2054086A1 (de) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG Konjugat aus einem antikörper gegen ccr5 und einem antifusogenen peptid
CN101516914A (zh) 2006-09-29 2009-08-26 霍夫曼-拉罗奇有限公司 针对ccr5的抗体及其应用
US7939083B2 (en) * 2006-10-23 2011-05-10 Progenics Pharmaceuticals Inc. Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
AU2011286024B2 (en) 2010-08-02 2014-08-07 Macrogenics, Inc. Covalent diabodies and uses thereof
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103068847B (zh) * 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
AU2011312562B2 (en) * 2010-09-27 2014-10-09 Sangamo Therapeutics, Inc. Methods and compositions for inhibiting viral entry into cells
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
KR102060389B1 (ko) 2011-05-21 2019-12-31 마크로제닉스, 인크. 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
SMT202100464T1 (it) 2013-03-14 2021-11-12 Macrogenics Inc Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione
EP3027755B1 (de) * 2013-08-02 2019-10-09 The Regents of The University of California Manipulation von antiviraler t-zell-immunität durch stammzellen und chimäre antigenrezeptoren
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
KR20160089390A (ko) * 2013-12-10 2016-07-27 에프. 호프만-라 로슈 아게 다중-하부단위 구조에 대한 약학적 활성 개체의 표적화 전달을 위한 다중-하부단위 구조의 하부단위의 결합 도메인의 용도
KR20160135190A (ko) 2014-02-14 2016-11-25 앤드류 에스. 카이 혈관형성 암의 치료를 위한 개선된 방법
MX386297B (es) 2014-09-29 2025-03-18 Univ Duke Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
EP3227332B1 (de) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispezifische antikörper
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
BR112019013468A8 (pt) 2016-12-27 2022-11-22 Univ Rockefeller Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
EP3641806A4 (de) 2017-06-22 2021-06-23 University of Maryland, Baltimore Breit neutralisierende antikörper gegen hiv
EP3762033A4 (de) * 2018-03-09 2021-12-08 Atreca, Inc. Anti-hiv-antikörper
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
AU3662293A (en) 1992-02-10 1993-09-03 Progenics Pharmaceuticals, Inc. A method of using cd4-containing molecules to substantially reduce the risk of occupational hiv transmission
FI951488L (fi) 1992-09-30 1995-05-23 Scripps Research Inst Ihmisen immuunikatoviruksen vastaiset ihmisen neutraloivat monoklonaaliset vasta-aineet
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5925741A (en) * 1992-12-31 1999-07-20 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
EP0699077B1 (de) * 1993-05-07 2001-10-31 Akzo Nobel N.V. Hiv immunogene komplexe
WO1995011317A1 (en) 1993-10-19 1995-04-27 The Scripps Research Institute Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
JPH10509237A (ja) 1994-11-10 1998-09-08 ザ スクリップス リサーチ インスティテュート 中和抗体の誘発のための防御抗原を同定する方法
US6852703B1 (en) 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
US7048929B1 (en) 1997-11-10 2006-05-23 Dana-Farber Cancer Institute, Inc. Stabilized primate lentivirus envelope glycoproteins
US6135941A (en) 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
CA2359892A1 (en) 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
CA2361292C (en) 1999-03-16 2012-05-29 Edward A. Berger A novel chimeric protein for prevention and treatment of hiv infection
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
ATE421976T1 (de) 1999-05-18 2009-02-15 Dyax Corp Fab fragmentbibliotheken und verfahren für deren verwendung
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
JP2004511444A (ja) 2000-09-22 2004-04-15 デューク・ユニバーシティー 免疫原
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE10123041A1 (de) 2001-05-11 2002-11-28 Tobias Heintges Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
CA2484930A1 (en) 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2003095492A1 (en) * 2002-05-06 2003-11-20 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies

Also Published As

Publication number Publication date
EP1450857A2 (de) 2004-09-01
EP1450857B1 (de) 2010-09-15
US20040259075A1 (en) 2004-12-23
WO2003033666A3 (en) 2004-06-24
WO2003033666A2 (en) 2003-04-24
US7378093B2 (en) 2008-05-27
US20070212349A1 (en) 2007-09-13
CA2463931A1 (en) 2003-04-24
AU2002337885B1 (en) 2003-04-28
US7223844B2 (en) 2007-05-29
DE60237704D1 (de) 2010-10-28
EP1450857A4 (de) 2006-01-18

Similar Documents

Publication Publication Date Title
ATE481109T1 (de) Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
WO2005000244A3 (en) Methods and compositions for treating rheumatoid arthritis
EP2400021A3 (de) Verfahren und Zusammensetzungen auf ErbB3-Basis zur Behandlung von Neoplasmen
WO2003048083A3 (en) Antibodies against monocyte chemotactic proteins
AU9399501A (en) Therapeutic antibodies
WO2002058717A3 (en) Methods for treating rheumatoid arthritis using il-17 antagonists
EP1064308A4 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE60219801D1 (de) KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
DE60135498D1 (de) Produktion von ganzen Antikörpern in prokaryontischen Zellen
PE20071055A1 (es) Anticuerpos anti mn
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
WO2003048207A3 (en) Anti-dota antibody
WO2006026703A8 (en) Chemical compounds
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
NO986088D0 (no) Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisi
DE60238555D1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
WO2003025019A8 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
EP3300739A3 (de) An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
EA200400134A1 (ru) Терапевтический агент
EP4269433A3 (de) Tgf-beta-rii-bindende proteine
WO2004067564B1 (en) Compositions against cancer antigen liv-1 and uses thereof
WO2004037997A3 (en) Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
WO2003068813A3 (en) Group b streptococcus antigen
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties